|1.||Tepper, Stewart J: 9 articles (09/2013 - 01/2004)|
|2.||Kori, Shashidhar H: 7 articles (02/2015 - 07/2008)|
|3.||Silberstein, Stephen D: 5 articles (05/2013 - 06/2007)|
|4.||Silberstein, Stephen: 4 articles (09/2012 - 11/2006)|
|5.||Baron, Eric P: 3 articles (05/2015 - 09/2010)|
|6.||Kabbouche, Marielle A: 3 articles (01/2015 - 01/2009)|
|7.||Hershey, Andrew D: 3 articles (01/2015 - 01/2009)|
|8.||Rapoport, Alan M: 3 articles (05/2012 - 01/2004)|
|9.||Charles, James A: 3 articles (05/2010 - 02/2005)|
|10.||Shrewsbury, Stephen B: 3 articles (11/2009 - 07/2008)|
|1.||Migraine Disorders (Migraine)
01/01/1990 - "Repeated dosing of dihydroergotamine has proven to be remarkably effective in stabilizing the mechanism of migraine, allowing these patients to make the transition to a more reasonable as well as more specific form of therapy."
03/01/1996 - "Dihydroergotamine use by home injection can be an effective treatment for a significant proportion of patients with severe migraine including patients with transformed migraine and medication overuse."
10/01/2011 - "To evaluate the efficacy of MAP0004, an orally inhaled dihydroergotamine, for acute treatment of migraine when administered at various time points from within 1 hour to more than 8 hours after migraine onset. "
08/01/1992 - "Although there is little evidence from double-blind clinical trials, dihydroergotamine does appear to be effective in the treatment of acute attacks and in the prevention of migraine. "
10/01/2010 - "Dihydroergotamine is an effective treatment of migraine. "
06/01/2007 - "Dihydroergotamine is often effective for patients whose refractory headaches have failed prior triptan therapy. "
10/01/1992 - "The efficacy of the repetitive intravenous dihydroergotamine (DHE) inpatient protocol for refractory headache is well established. "
01/01/1992 - "This study examines the practicality and efficacy of dihydroergotamine mesylate (DHE) when self-administered subcutaneously in a population of refractory headache patients. "
09/01/2010 - "The role of ergots in headache should be revisited, especially in view of newer ergot formulations with improved tolerability and side effect profiles, such as orally inhaled dihydroergotamine. "
10/01/2006 - "To evaluate the safety and efficacy of a repetitive intranasal (IN) dihydroergotamine (DHE) burst protocol for treatment of refractory headaches. "
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
02/01/1985 - "The sensitivity of impedance plethysmography (IPG) for diagnosing deep vein thrombosis was evaluated in the presence of dihydroergotamine, an agent with significant venoconstrictor activity. "
12/01/1981 - "Prevention and treatment of early postoperative deep vein thrombosis in africans: a Nigerian experience with dihydroergotamine mesylate."
10/02/1981 - "This effect of dihydroergotamine, apart from the vasoactive properties of this compound, might prove advantageous as a prophylactic measure in venous thrombosis."
04/01/1993 - "The effects of dihydroergotamine (DHE) on the circulation of the leg during combined epidural and general anaesthesia were studied to determine if DHE would enhance leg blood flow and prevent postoperative deep vein thrombosis in a double-blind trial of 40 elderly female patients subjected to cholecystectomy. "
04/01/1993 - "Effect of dihydroergotamine on leg blood flow during combined epidural and general anaesthesia and postoperative deep vein thrombosis after cholecystectomy."
|4.||Headache Disorders (Headache Syndromes)
03/01/1992 - "Renewed interest in its use has been kindled by research in receptor pharmacology and by efficacy of DHE-45 in breaking the cycle of chronic daily headache. "
05/01/2010 - "We conducted a study to determine efficacy, tolerability, and feasibility to treat patients with daily intractable headache with continuous intravenous dihydroergotamine in an outpatient home-based setting. "
05/01/1998 - "In-patient treatment of chronic daily headache using dihydroergotamine: a long-term follow-up study."
03/01/1997 - "Continuous intravenous dihydroergotamine in the treatment of intractable headache."
05/01/2010 - "Established consecutive-day inpatient intravenous dihydroergotamine protocols administered by bolus intravenous injection or continuous infusion injection in the hospital have demonstrated efficacy and safety in modifying the course of daily intractable headache. "
09/01/2000 - "Two days of intravenous dihydroergotamine resolved his pain. "
03/20/1999 - "Factors for a favourable prognosis are the length of the abuse period (less than 5 years), the use of dihydergot as a pain-killer, motivation of the patient and the support of the family and the patient's immediate environment."
12/01/1996 - "The 2-mg dihydroergotamine mesylate dose provided slightly superior pain relief and was associated with fewer adverse events compared with the 3-mg dihydroergotamine mesylate dose. "
11/02/1987 - "The dihydroergotamine-treated group experienced a shorter duration of the over-all attack until healed skin reappeared, with a shorter duration of both pain and oedema, than did the placebo-treated group. "
08/15/1987 - "Intravenous dihydroergotamine to relieve pelvic congestion with pain in young women."
|2.||Ergotamine (Ergotamine Tartrate)
|8.||Aspirin (Acetylsalicylic Acid)
|9.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|10.||Valproic Acid (Valproate, Semisodium)
|1.||Hip Replacement Arthroplasty (Total Hip Replacement)
|2.||Metered Dose Inhalers (Metered Dose Inhaler)
|3.||Gynecologic Surgical Procedures (Gynecologic Surgery)
|5.||Intermittent Pneumatic Compression Devices